Observational studyBreast cancer research : BCR2026
Real-world data for a CDK4/6 inhibitor, palbociclib, as 1st- or 2nd-line therapy in HR+/HER2- metastatic breast cancer: a multicenter prospective cohort study.
Takashi Ishikawa et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.